# Nuclide record stampede (trial). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/trials/stampede/>
  a schema:MedicalTrial ;
  nuclide:kind "trial" ;
  schema:identifier "stampede", "NCT00268476" ;
  schema:name "STAMPEDE"@en ;
  schema:alternateName "STAMPEDE trial"@en, "MRC PR08"@en, "Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy"@en, "STAMPEDE platform"@en ;
  schema:description "STAMPEDE is the longest-running platform trial in oncology, and showed that both docetaxel and abiraterone extend life when started at first diagnosis of metastatic disease."@en ;
  schema:url <https://nuclide.cc/trials/stampede/> ;
  schema:dateModified "2026-09-06"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT00268476>, <https://doi.org/10.1016/S0140-6736(15)01037-5>, <https://doi.org/10.1056/NEJMoa1702900>, <https://doi.org/10.1016/S0140-6736(18)32486-3>, <https://doi.org/10.1016/S0140-6736(21)02437-5>, <https://doi.org/10.1016/S1470-2045(23)00148-1>, <https://doi.org/10.1016/S0140-6736(21)00100-8>, <https://www.stampedetrial.org> ;
  nuclide:status "positive" ;
  nuclide:phase "platform" ;
  nuclide:indications <https://nuclide.cc/indications/prostate/>, <https://nuclide.cc/indications/prostate-mhspc/>, <https://nuclide.cc/indications/prostate-high-risk/> ;
  nuclide:drugs <https://nuclide.cc/drugs/abiraterone/>, <https://nuclide.cc/drugs/docetaxel/>, <https://nuclide.cc/drugs/enzalutamide/> ;
  nuclide:institutions <https://nuclide.cc/institutions/royal-marsden/> ;
  nuclide:terms <https://nuclide.cc/terms/mcrpc-mhspc/> ;
  nuclide:people <https://nuclide.cc/people/silke-gillessen/> .